Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Table 1: Demographics

Characteristics	Total N=26 (N [%])
Median age (range), years	74 (range 51-94)
Sex	
Male	19 (73.1%)
Female	7 (26.9%)
Race	
White	24 (92.3%)
Black	1 (3.8%)
Unknown	1 (3.8%)
TNM Stage	
T2 N0 M0	10 (38.5%)
T3 N0 M0	6 (23.1%)
T4 N0 M0	2 (7.6%)
T2-4 N1-2 M0	8 (30.8%)
Unresectable	
Yes	9 (34.6%)
No	17 (65.4%)
Unfit for surgery	
Yes	13 (50%)
No	13 (50%)
Cisplatin ineligible	
Yes	23 (88.5%)
No	3 (11.5%)
ECOG Status	
0 – 1	19 (73.1%)
2	7 (26.9%)
Extent of TURBT per urologist	
Complete	19 (73.1%)
Incomplete	7 (26.95)
Presence of Hydronephrosis	
Yes	7 (26.9%)
No	19 (73.1%)
Neoadjuvant chemotherapy exposure	
Yes	4 (15.4%)
No	22 (84.6%)
Tumor PD-L1 status	
Positive	10 (38.5%)
Negative	16 (61.5%)
Histology	
Pure urothelial	15 (57.7%)
Mixed urothelial with variant*	11 (42.3%)

*Mixed variants histology in addition to pure urothelial component included: squamous =3; sarcomatoid=1;micropapillary=1; glandular=4; sarcomatoid+ squamous=1; micropapillary+ glandular=1. Please refer to supplementary table 1 for further details.